SPY443.18+5.32 1.22%
DIA347.56+5.06 1.48%
IXIC15,052.24+155.40 1.04%

BRIEF-Merck And Ridgeback Biotherapeutics Announce Initiation Of Pivotal Phase 3 Move-Ahead Study Evaluating Molnupiravir For Post-Exposure Prophylaxis Of Covid-19 Infection

reuters.com · 09/01/2021 07:33
BRIEF-Merck And Ridgeback Biotherapeutics Announce Initiation Of Pivotal Phase 3 Move-Ahead Study Evaluating Molnupiravir For Post-Exposure Prophylaxis Of Covid-19 Infection

- Merck & Co Inc MRK:

  • MERCK AND RIDGEBACK BIOTHERAPEUTICS ANNOUNCE INITIATION OF PIVOTAL PHASE 3 MOVE-AHEAD STUDY EVALUATING MOLNUPIRAVIR FOR POST-EXPOSURE PROPHYLAXIS OF COVID-19 INFECTION

  • MERCK & CO INC - STUDY NOW ENROLLING PARTICIPANTS WHO LIVE IN SAME HOUSEHOLD AS SOMEONE WITH SYMPTOMATIC, LABORATORY-CONFIRMED COVID-19

  • MERCK & CO INC - STUDY NOW ENROLLING PARTICIPANTS WHO LIVE IN SAME HOUSEHOLD AS SOMEONE WITH SYMPTOMATIC, LABORATORY-CONFIRMED COVID-19

  • MERCK & CO INC - DATA FROM STUDY IS EXPECTED IN SECOND HALF OF 2021.

  • MERCK & CO INC - SAFETY AND EFFICACY OF MOLNUPIRAVIR IS ALSO CURRENTLY BEING EVALUATED IN PART 2 OF ONGOING MOVE-OUT TRIAL

Source text for Eikon: ID:nBw9zFKT3a

Further company coverage: MRK


((Reuters.Briefs@thomsonreuters.com;))